About bausch health cos. inc. - BHC
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.
BHC At a Glance
Bausch Health Cos., Inc.
2150 St. Elzéar Boulevard West
Laval, Québec H7L 4A8
Phone | 1-514-744-6792 | Revenue | 8.76B | |
Industry | Pharmaceuticals: Other | Net Income | -592,000,000.00 | |
Sector | Health Technology | 2023 Sales Growth | 7.792% | |
Fiscal Year-end | 12 / 2024 | Employees | 20,270 | |
View SEC Filings |
BHC Valuation
P/E Current | N/A |
P/E Ratio (with extraordinary items) | N/A |
P/E Ratio (without extraordinary items) | N/A |
Price to Sales Ratio | 0.336 |
Price to Book Ratio | N/A |
Price to Cash Flow Ratio | 2.953 |
Enterprise Value to EBITDA | 8.909 |
Enterprise Value to Sales | 2.914 |
Total Debt to Enterprise Value | 0.886 |
BHC Efficiency
Revenue/Employee | 432,017.76 |
Income Per Employee | -29,205.723 |
Receivables Turnover | 4.383 |
Total Asset Turnover | 0.33 |
BHC Liquidity
Current Ratio | 1.301 |
Quick Ratio | 0.942 |
Cash Ratio | 0.224 |
BHC Profitability
Gross Margin | 58.479 |
Operating Margin | 18.271 |
Pretax Margin | -4.454 |
Net Margin | -6.76 |
Return on Assets | -2.232 |
Return on Equity | N/A |
Return on Total Capital | -2.744 |
Return on Invested Capital | -2.896 |
BHC Capital Structure
Total Debt to Total Equity | N/A |
Total Debt to Total Capital | 104.737 |
Total Debt to Total Assets | 82.622 |
Long-Term Debt to Equity | N/A |
Long-Term Debt to Total Capital | 102.368 |